Side effects included previously published inflammatory syndromes caused by CAR-T cell therapy, most notably tumor inflammation-associated neurotoxicity, which was managed with corticosteroids and monoclonal antibodies directed against IL-1 (anakinra) and IL-6 (tocilizumab or siltuximab). Here, IL1B is linked to neoplasm.